Prof. Orna Mor was appointed as the Head of the National HIV Reference Center in 2010 and director of the Clinical Virology Laboratory in the Central Virology Laboratory of the Ministry of Health in 2011. Since 2013, she has been the head of the Viral Hepatitis Reference Center. Previously, she had worked in the biotech & pharmaceutical industry for more than 13 years. Her former experience includes human genetics, cancer research, gene and drug development projects, clinical development, patent applications, and scientific due diligence. In the clinical virology laboratory, she leads the national confirmation of HIV infection and is engaged in molecular epidemiology research in the fields of HIV, viral hepatitis, and Parvovirus B19.
Prof. Orna Mor holds a Ph.D. degree from the Faculty of Medicine at Tel Aviv University, as well as a Master of Business Administration (MBA) degree from the Recanati Faculty of Management, both at Tel Aviv University.
In October 2017, she joined the Department of Epidemiology and Preventive Medicine, School of Public Health, Faculty of Medical and Health Sciences, at Tel Aviv University as a Senior Lecturer, and in 2022, she was promoted to Associate Professor
Clinical Virology; HIV- Laboratory diagnosis, molecular epidemiology, drug resistance; Viral hepatitis: from A to E; Parvovirus B19
My main interest is laboratory diagnosis, epidemiology, sequencing and molecular analysis of HIV, viral hepatitis and Parvovirus B19. I have pioneered the introduction of next generation sequencing technology as ש routine tool for clinical virology. Our studies demonstrate the yearly changes in HIV-1 epidemiology in Israel, assess the main risk groups and the circulation of resistance mutations. Other studies demonstrate the prevalence Parvovirus B19, HEV and HDV infection in Israel and assessed related factors. We are strongly engaged in the characterization of patients with chronic HBV and HCV infections. During the COVID-19 pandemic I was deeply involved in the assessment and implementation of different diagnostic tools in Israel.
https://pubmed.ncbi.nlm.nih.gov/?term=orna+mor
1: Tzou PL, Rhee SY, Descamps D, Clutter DS, Hare B, Grude M, Parkin N,
Jordan MR, Bertagnolio S, Schapiro JM, Harrigan PR, Geretti AM, Marcelin AG,
Shafer RW; WHO HIVResNet Working Groups. Integrase strand transfer inhibitor
(INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug
resistance. J Antimicrob Chemother. 2020 Jan 1;75(1):170-182.
2: Deutsch L, Houri I, Ben-Ari Z, Shlomai A, Veitsman E, Cohen-Ezra O, Issachar
A, Mor O, Gozlan Y, Bruck R, Menachem Y, Zelber-Sagi S, Katchman H, Shibolet O.
Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease
inhibitors failure - a prospective multi-centre trial. BMC Infect Dis. 2020 Apr
3;20(1):264.
3: Berg MG, Olivo A, Forberg K, Harris BJ, Yamaguchi J, Shirazi R, Gozlan Y,
Sauleda S, Kaptue L, Rodgers MA, Mor O, Cloherty GA. Advanced molecular
surveillance approaches for characterization of blood borne hepatitis viruses.
PLoS One. 2020 Jul 17;15(7):e0236046.
4: Zuckerman NS, Pando R, Bucris E, Drori Y, Lustig Y, Erster O, Mor O,
Mendelson E, Mandelboim M. Comprehensive Analyses of SARS-CoV-2 Transmission in
a Public Health Virology Laboratory. Viruses. 2020 Aug 5;12(8):854.
5: Wagner T, Olshtain-Pops K, Wax M, Horwitz O, Shirazi R, Gozlan Y, Volnowitz
H, Mendelson E, Levy I, Mor O. HIV-1 infection among women in Israel, 2010-2018.
BMC Infect Dis. 2020 Sep 7;20(1):660.
6: Etzion O, Dahari H, Yardeni D, Issachar A, Nevo-Shor A, Cohen-Naftaly M,
Ashur Y, Uprichard SL, Arbib OS, Munteanu D, Braun M, Cotler SJ, Abufreha N,
Keren-Naus A, Shemer-Avni Y, Mor O, Murad J, Novack V, Shlomai A. Response
guided therapy for reducing duration of direct acting antivirals in chronic
hepatitis C infected patients: a Pilot study. Sci Rep. 2020 Oct 20;10(1):17820.
7: Hemelaar J, Elangovan R, Yun J, Dickson-Tetteh L, Kirtley S, Gouws-Williams
E, Ghys PD; WHO-UNAIDS Network for HIV Isolation and Characterisation. Global
and regional epidemiology of HIV-1 recombinants in 1990-2015: a systematic
review and global survey. Lancet HIV. 2020 Nov;7(11):e772-e781.
8: Gelbart M, Harari S, Ben-Ari Y, Kustin T, Wolf D, Mandelboim M, Mor O,
Pennings PS, Stern A. Drivers of within-host genetic diversity in acute
infections of viruses. PLoS Pathog. 2020 Nov 4;16(11):e1009029.
9: Indenbaum V, Koren R, Katz-Likvornik S, Yitzchaki M, Halpern O, Regev-Yochay
G, Cohen C, Biber A, Feferman T, Cohen Saban N, Dhan R, Levin T, Gozlan Y, Weil
M, Mor O, Mandelboim M, Sofer D, Mendelson E, Lustig Y. Testing IgG antibodies
against the RBD of SARS-CoV-2 is sufficient and necessary for COVID-19
diagnosis. PLoS One. 2020 Nov 23;15(11):e0241164.
10: Gozlan Y, Bar-Or I, Volnowitz H, Asulin E, Rich R, Anis E, Shemer Y,
Szwarcwort Cohen M, Dahary EL, Schreiber L, Goldiner I, Rozenberg O, Picard O,
Savion M, Fuchs I, Mendelson E, Mor O. Lessons from intensified surveillance of
viral hepatitis A, Israel, 2017 and 2018. Euro Surveill. 2021 Feb;26(6):2000001.
11: Zuckerman NS, Bucris E, Drori Y, Erster O, Sofer D, Pando R, Mendelson E,
Mor O, Mandelboim M. Genomic variation and epidemiology of SARS-CoV-2
importation and early circulation in Israel. PLoS One. 2021 Mar
26;16(3):e0243265.
12: Erster O, Shkedi O, Benedek G, Zilber E, Varkovitzky I, Shirazi R, Oriya
Shorka D, Cohen Y, Bar T, Yechieli R, Tepperberg Oikawa M, Venkert D, Linial M,
Oiknine-Djian E, Mandelboim M, Livneh Z, Shenhav-Saltzman G, Mendelson E, Wolf
D, Szwarcwort-Cohen M, Mor O, Lewis Y, Zeevi D. Improved sensitivity, safety,
and rapidity of COVID-19 tests by replacing viral storage solution with lysis
buffer. PLoS One. 2021 Mar 30;16(3):e0249149.
13: Zuckerman NS, Fleishon S, Bucris E, Bar-Ilan D, Linial M, Bar-Or I,
Indenbaum V, Weil M, Lustig Y, Mendelson E, Mandelboim M, Mor O, Zuckerman N, On
Behalf Of The Israel National Consortium For Sars-CoV-Sequencing. A Unique SARS-
CoV-2 Spike Protein P681H Variant Detected in Israel. Vaccines (Basel). 2021 Jun
8;9(6):616.
14: Gozlan Y, Reingold S, Koren R, Halpern O, Regev-Yochay G, Cohen C, Biber A,
Picard O, Mendelson E, Lustig Y, Mor O. SARS-CoV-2 outbreak in a synagogue
community: longevity and strength of anti-SARS-CoV-2 IgG responses. Epidemiol
Infect. 2021 Jun 24;149:e153.
15: Lustig Y, Zuckerman N, Nemet I, Atari N, Kliker L, Regev-Yochay G, Sapir E,
Mor O, Alroy-Preis S, Mendelson E, Mandelboim M. Neutralising capacity against
Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2,
BioNTech/Pfizer) vaccination in health care workers, Israel. Euro Surveill. 2021
Jul;26(26):2100557.
16: Elangovan R, Jenks M, Yun J, Dickson-Tetteh L, Kirtley S, Hemelaar J; WHO-
UNAIDS Network for HIV Isolation and Characterisation. Global and Regional
Estimates for Subtype-Specific Therapeutic and Prophylactic HIV-1 Vaccines: A
Modeling Study. Front Microbiol. 2021 Jul 15;12:690647.
17: Zuckerman NS, Bucris E, Erster O, Mandelboim M, Adler A, Burstein S, Protter
N, Szwarcwort-Cohen M, Mendelson E, Mor O. Prolonged detection of complete viral
genomes demonstrated by SARS-CoV-2 sequencing of serial respiratory specimens.
PLoS One. 2021 Aug 5;16(8):e0255691.
18: Mor O, Mandelboim M, Fleishon S, Bucris E, Bar-Ilan D, Linial M, Nemet I,
Kliker L, Lustig Y, Israel National Consortium For Sars-CoV-Sequencing,
Mendelson ES, Zuckerman NS. The Rise and Fall of a Local SARS-CoV-2 Variant with
the Spike Protein Mutation L452R. Vaccines (Basel). 2021 Aug 23;9(8):937.
19: Shitrit P, Zuckerman NS, Mor O, Gottesman BS, Chowers M. Nosocomial outbreak
caused by the SARS-CoV-2 Delta variant in a highly vaccinated population,
Israel, July 2021. Euro Surveill. 2021 Sep;26(39):2100822.
20: Goldenfeld M, Zuckerman N, Amit S, Tal I, Hasson S, Gefen-Halevi S, Biber A,
Mor O, Regev-Yochay G. First reported nosocomial SARS-CoV-2 outbreak in a
hospital-based laundry facility. Epidemiol Infect. 2021 Sep 15;150:e18.
21: O'Toole Á, Hill V, Pybus OG, Watts A, Bogoch II, Khan K, Messina JP;
COVID-19 Genomics UK (COG-UK) consortium; Network for Genomic Surveillance in
South Africa (NGS-SA); Brazil-UK CADDE Genomic Network; Tegally H, Lessells RR,
Giandhari J, Pillay S, Tumedi KA, Nyepetsi G, Kebabonye M, Matsheka M, Mine M,
Tokajian S, Hassan H, Salloum T, Merhi G, Koweyes J, Geoghegan JL, de Ligt J,
Ren X, Storey M, Freed NE, Pattabiraman C, Prasad P, Desai AS, Vasanthapuram R,
Schulz TF, Steinbrück L, Stadler T; Swiss Viollier Sequencing Consortium; Parisi
A, Bianco A, García de Viedma D, Buenestado-Serrano S, Borges V, Isidro J,
Duarte S, Gomes JP, Zuckerman NS, Mandelboim M, Mor O, Seemann T, Arnott A,
Draper J, Gall M, Rawlinson W, Deveson I, Schlebusch S, McMahon J, Leong L, Lim
CK, Chironna M, Loconsole D, Bal A, Josset L, Holmes E, St George K, Lasek-
Nesselquist E, Sikkema RS, Oude Munnink B, Koopmans M, Brytting M, Sudha Rani V,
Pavani S, Smura T, Heim A, Kurkela S, Umair M, Salman M, Bartolini B, Rueca M,
Drosten C, Wolff T, Silander O, Eggink D, Reusken C, Vennema H, Park A,
Carrington C, Sahadeo N, Carr M, Gonzalez G; SEARCH Alliance San Diego; National
Virus Reference Laboratory; SeqCOVID-Spain; Danish Covid-19 Genome Consortium
(DCGC); Communicable Diseases Genomic Network (CDGN); Dutch National SARS-CoV-2
surveillance program; Division of Emerging Infectious Diseases (KDCA); de
Oliveira T, Faria N, Rambaut A, Kraemer MUG. Tracking the international spread
of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2 with grinch. Wellcome Open
Res. 2021 Sep 17;6:121.
22: Wand O, Mor O, Zuckerman N, Fadeela A, Benchetrit S, Nacasch N, Cohen-Hagai
K. Outcomes From Infections With Variant Strains of SARS-CoV-2 Among Patients
Receiving Maintenance Hemodialysis. Am J Kidney Dis. 2021 Oct;78(4):617-619.
23: Bar-Or I, Weil M, Indenbaum V, Bucris E, Bar-Ilan D, Elul M, Levi N, Aguvaev
I, Cohen Z, Shirazi R, Erster O, Sela-Brown A, Sofer D, Mor O, Mendelson E,
Zuckerman NS. Detection of SARS-CoV-2 variants by genomic analysis of wastewater
samples in Israel. Sci Total Environ. 2021 Oct 1;789:148002.
24: David D, Kedem E, Turner D, Levy I, Elbirt DG, Shahar E, Istumin V, Mor O,
Chowers M, Elinav H. Long term dual antiretroviral therapy: A real life
retrospective countrywide Israeli study. PLoS One. 2021 Oct 29;16(10):e0259271.
25: Erster O, Mendelson E, Levy V, Kabat A, Mannasse B, Asraf H, Azar R, Ali Y,
Shirazi R, Bucris E, Bar-Ilan D, Mor O, Mandelboim M, Sofer D, Fleishon S,
Zuckerman NS. Rapid and High-Throughput Reverse Transcriptase Quantitative PCR
(RT-qPCR) Assay for Identification and Differentiation between SARS-CoV-2
Variants B.1.1.7 and B.1.351. Microbiol Spectr. 2021 Oct 31;9(2):e0050621
26: Zuckerman N, Nemet I, Kliker L, Atari N, Lustig Y, Bucris E, Bar Ilan D,
Geva M, Sorek-Abramovich R, Weiner C, Rainy N, Bar-Chaim A, Benveniste-Levkovitz
P, Abu Hamed R, Regev-Yochay G, Hevkin O, Mor O, Alroy-Preis S, Mendelson E,
Mandelboim M. The SARS-CoV-2 Lambda variant and its neutralisation efficiency
following vaccination with Comirnaty, Israel, April to June 2021. Euro Surveill.
2021 Nov;26(45):2100974.
27: Shirazi R, Pozzi P, Gozlan Y, Wax M, Lustig Y, Linial M, Mendelson E,
Bardenstein S, Mor O. Identification of Hepatitis E Virus Genotypes 3 and 7 in
Israel: A Public Health Concern? Viruses. 2021 Nov 22;13(11):2326.
28: Davidov-Derevynko Y, Ben Yakov G, Wieder A, Segal G, Naveh L, Orlova N,
Gringauz I, Amit S, Mor O, Klempfner R, Rahav G, Ben Ari Z. The liver in severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Eur J
Gastroenterol Hepatol. 2021 Dec 1;33(1S Suppl 1):e313-e319.
29: Levy I, Wieder-Finesod A, Litchevsky V, Biber A, Indenbaum V, Olmer L,
Huppert A, Mor O, Goldstein M, Levin EG, Hod T, Cohen C, Lustig Y, Rahav G.
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living
with HIV-1. Clin Microbiol Infect. 2021 Dec;27(12):1851-1855.
30: Singer SR, Angulo FJ, Swerdlow DL, McLaughlin JM, Hazan I, Ginish N, Anis E,
Mendelson E, Mor O, Zuckerman NS, Erster O, Southern J, Pan K, Mircus G,
Lipsitch M, Haas EJ, Jodar L, Levy Y, Alroy-Preis S. Effectiveness of BNT162b2
mRNA COVID-19 vaccine against SARS-CoV-2 variant Beta (B.1.351) among persons
identified through contact tracing in Israel: A prospective cohort study.
EClinicalMedicine. 2021 Dec;42:101190.
31: Brito AF, Semenova E, Dudas G, Hassler GW, Kalinich CC, Kraemer MUG, Ho J,
Tegally H, Githinji G, Agoti CN, Matkin LE, Whittaker C; Danish Covid-19 Genome
Consortium; COVID-19 Impact Project; Network for Genomic Surveillance in South
Africa (NGS-SA); GISAID core curation team; Howden BP, Sintchenko V, Zuckerman
NS, Mor O, Blankenship HM, de Oliveira T, Lin RTP, Siqueira MM, Resende PC,
Vasconcelos ATR, Spilki FR, Aguiar RS, Alexiev I, Ivanov IN, Philipova I,
Carrington CVF, Sahadeo NSD, Gurry C, Maurer-Stroh S, Naidoo D, von Eije KJ,
Perkins MD, van Kerkhove M, Hill SC, Sabino EC, Pybus OG, Dye C, Bhatt S,
Flaxman S, Suchard MA, Grubaugh ND, Baele G, Faria NR. Global disparities in
SARS-CoV-2 genomic surveillance. medRxiv [Preprint]. 2021 Dec
9:2021.08.21.21262393.
32: Popping S, Cento V, Seguin-Devaux C, Boucher CAB, de Salazar A, Heger E, Mor
O, Sayan M, Salmon-Ceron D, Weis N, Krarup HB, de Knegt RJ, Săndulescu O,
Chulanov V, van de Vijver DAMC, García F, Ceccherini-Silberstein F. The European
Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral
Failures. Viruses. 2021 Dec 22;14(1):16.
33: Wagner T, Zuckerman NS, Halperin T, Chemtob D, Levy I, Elbirt D, Shachar E,
Olshtain-Pops K, Elinav H, Chowers M, Itsomin V, Riesenberg K, Wax M, Shirazi R,
Gozlan Y, Matus N, Girshengorn S, Marom R, Mendelson E, Turner D, Mor O.
Epidemiology and Transmitted HIV-1 Drug Resistance among Treatment-Naïve
Individuals in Israel, 2010-2018. Viruses. 2021 Dec 31;14(1):71.
34: Fass E, Zizelski Valenci G, Rubinstein M, Freidlin PJ, Rosencwaig S, Kutikov
I, Werner R, Ben-Tovim N, Bucris E, Erster O, Zuckerman NS, Mor O, Mendelson E,
Dveyrin Z, Rorman E, Nissan I. HiSpike Method for High-Throughput Cost Effective
Sequencing of the SARS-CoV-2 Spike Gene. Front Med (Lausanne). 2022 Jan
11;8:798130.
35: Mor O, Zuckerman NS, Hazan I, Fluss R, Ash N, Ginish N, Mendelson E, Alroy-
Preis S, Freedman L, Huppert A. BNT162b2 vaccine effectiveness was marginally
affected by the SARS-CoV-2 beta variant in fully vaccinated individuals. J Clin
Epidemiol. 2022 Feb;142:38-44.
36: Davidov Y, Tsaraf K, Cohen-Ezra O, Likhter M, Ben Yakov G, Levy I, Levin EG,
Lustig Y, Mor O, Rahav G, Ben Ari Z. Immunogenicity and Adverse Effects of the
2-Dose BNT162b2 Messenger RNA Vaccine Among Liver Transplantation Recipients.
Liver Transpl. 2022 Feb;28(2):215-223.
37: Gozlan Y, Aaron D, Davidov Y, Likhter M, Ben Yakov G, Cohen-Ezra O, Picard
O, Erster O, Mendelson E, Ben-Ari Z, Abu Baker F, Mor O. HBV-RNA, Quantitative
HBsAg, Levels of HBV in Peripheral Lymphocytes and HBV Mutation Profiles in
Chronic Hepatitis B. Viruses. 2022 Mar 11;14(3):584.
38: Erster O, Mendelson E, Kabat A, Levy V, Mannasse B, Assraf H, Azar R, Ali Y,
Bucris E, Bar-Ilan D, Mor O, Elul M, Mandelboim M, Sofer D, Fleishon S,
Zuckerman NS, Bar-Or I. Specific Detection of SARS-CoV-2 Variants B.1.1.7
(Alpha) and B.1.617.2 (Delta) Using a One-Step Quantitative PCR Assay. Microbiol
Spectr. 2022 Apr 27;10(2):e0217621.
39: Howe AYM, Rodrigo C, Cunningham EB, Douglas MW, Dietz J, Grebely J, Popping
S, Sfalcin JA, Parczewski M, Sarrazin C, de Salazar A, Fuentes A, Sayan M, Quer
J, Kjellin M, Kileng H, Mor O, Lennerstrand J, Fourati S, Di Maio VC, Chulanov
V, Pawlotsky JM, Harrigan PR, Ceccherini-Silberstein F, Garcia F; SHARED
Collaborators. Characteristics of hepatitis C virus resistance in an
international cohort after a decade of direct-acting antivirals. JHEP Rep. 2022
Feb 24;4(5):100462.
40: Lasmanovich R, Shaked O, Sivan A, Barak I, Nahari M, Mor O, Katchman H.
Hepatitis C Virus Prevalence, Medical Status Awareness and Treatment Engagement
among Homeless People Who use Drugs: Results of a Street Outreach Study. Subst
Abuse. 2022 May 26;16:11782218221095871.
41: Cohen Y, Bamberger N, Mor O, Walfisch R, Fleishon S, Varkovitzky I, Younger
A, Levi DO, Kohn Y, Steinberg DM, Zeevi D, Erster O, Mendelson E, Livneh Z.
Effective bubble-based testing for SARS-CoV-2 using swab-pooling. Clin Microbiol
Infect. 2022 Jun;28(6):859-864.
42: Bar-Or I, Indenbaum V, Weil M, Elul M, Levi N, Aguvaev I, Cohen Z, Levy V,
Azar R, Mannasse B, Shirazi R, Bucris E, Mor O, Sela Brown A, Sofer D, Zuckerman
NS, Mendelson E, Erster O. National Scale Real-Time Surveillance of SARS-CoV-2
Variants Dynamics by Wastewater Monitoring in Israel. Viruses. 2022 Jun
6;14(6):1229.
43: Szwarcwort-Cohen M, Wax M, Halutz O, Mendelson E, Mor O. Evaluation of
Biotrin, Serion and Euroimmun commercial assays for the detection of parvovirus
B19-specific IgM and IgG antibodies. Diagn Microbiol Infect Dis. 2022
Aug;103(4):115723.
44: Davidov Y, Indenbaum V, Tsaraf K, Cohen-Ezra O, Likhter M, Ben Yakov G,
Halperin R, Levy I, Mor O, Agmon-Levin N, Afek A, Rahav G, Lustig Y, Ben Ari Z.
A third dose of the BNT162b2 mRNA vaccine significantly improves immune
responses among liver transplant recipients. J Hepatol. 2022 Sep;77(3):702-709.
45: Wagner T, Zuckerman NS, Wax M, Shirazi R, Gozlan Y, Girshengorn S, Marom R,
Mendelson E, Turner D, Mor O. HIV-1 Circulating Recombinant Forms (CRFs) and
Unique Recombinant Forms (URFs) in Israel, 2010-2018. Viruses. 2022 Sep
6;14(9):1970.
46: Rom T, Levy I, Perlman S, Ziv-Baran T, Mor O. Determinants of Direct Costs
of HIV-1 Outpatient Care in Israel. Int J Environ Res Public Health. 2022 Nov
5;19(21):14542.
47: Brito AF, Semenova E, Dudas G, Hassler GW, Kalinich CC, Kraemer MUG, Ho J,
Tegally H, Githinji G, Agoti CN, Matkin LE, Whittaker C; Bulgarian SARS-CoV-2
sequencing group; Communicable Diseases Genomics Network (Australia and New
Zealand); COVID-19 Impact Project; Danish Covid-19 Genome Consortium; Fiocruz
COVID-19 Genomic Surveillance Network; GISAID core curation team; Network for
Genomic Surveillance in South Africa (NGS-SA); Swiss SARS-CoV-2 Sequencing
Consortium; Howden BP, Sintchenko V, Zuckerman NS, Mor O, Blankenship HM, de
Oliveira T, Lin RTP, Siqueira MM, Resende PC, Vasconcelos ATR, Spilki FR, Aguiar
RS, Alexiev I, Ivanov IN, Philipova I, Carrington CVF, Sahadeo NSD, Branda B,
Gurry C, Maurer-Stroh S, Naidoo D, von Eije KJ, Perkins MD, van Kerkhove M, Hill
SC, Sabino EC, Pybus OG, Dye C, Bhatt S, Flaxman S, Suchard MA, Grubaugh ND,
Baele G, Faria NR. Global disparities in SARS-CoV-2 genomic surveillance. Nat
Commun. 2022 Nov 16;13(1):7003.
48: Bar N, Bensoussan N, Rabinowich L, Levi S, Houri I, Ben-Ami Shor D, Shibolet
O, Mor O, Weitzman E, Turner D, Katchman H. Barriers and Facilitators of
Hepatitis C Care in Persons Coinfected with Human Immunodeficiency Virus. Int J
Environ Res Public Health. 2022 Nov 18;19(22):15237.
49: Davidov Y, Indenbaum V, Atari N, Kliker L, Tsaraf K, Asraf K, Cohen-Ezra O,
Likhter M, Mor O, Doolman R, Weiss-Ottolenghi Y, Hod T, Afek A, Kreiss Y, Lustig
Y, Regev-Yochay G, Mandelboim M, Ben-Ari Z. High Immune Response Rate to the
Fourth Boost of the BNT162b2 Vaccine against the Omicron Variants of Concern
among Liver Transplant Recipients. Viruses. 2022 Dec 12;14(12):2769.
50: Davidov Y, Indenbaum V, Mandelboim M, Asraf K, Gonen T, Tsaraf K, Cohen-Ezra
O, Likhter M, Nemet I, Kliker L, Mor O, Doolman R, Cohen C, Afek A, Kreiss Y,
Regev-Yochay G, Lustig Y, Ben-Ari Z. Reduced Neutralization Efficacy against
Omicron Variant after Third Boost of BNT162b2 Vaccine among Liver Transplant
Recipients. Viruses. 2023 Jan 16;15(1):253.
51: Vinograd A, Ben-David D, Gozlan Y, Mor O, Mor Z, Sheffer R, Savion M.
Hepatitis A virus transmission in a dental clinic setting. Infect Control Hosp
Epidemiol. 2023 Apr;44(4):692-693.
52: Nchinda N, Elangovan R, Yun J, Dickson-Tetteh L, Kirtley S, Hemelaar J; WHO-
UNAIDS Network for HIV Isolation and Characterisation. Global associations of
key populations with HIV-1 recombinants: a systematic review, global survey, and
individual participant data meta-analysis. Front Public Health. 2023 Jul
27;11:1153638.
53: Mbuagbaw L, Garcia C, Brenner B, Cecchini D, Chakroun M, Djiadeu P, Holguin
A, Mor O, Parkin N, Santoro MM, Ávila-Ríos S, Fokam J, Phillips A, Shafer RW,
Jordan MR. Checklist for studies of HIV drug resistance prevalence or incidence:
rationale and recommended use. Lancet HIV. 2023 Oct;10(10):e684-e689.
54: Lasmanovich R, Atias D, Mor O, Obolski U. False-positive HIV screening tests
during the COVID-19 pandemic, a passing trend? AIDS. 2023 Dec
1;37(15):2430-2432.
55: Wagner T, Levy I, Elbirt D, Shahar E, Olshtain-Pops K, Elinav H, Chowers M,
Istomin V, Riesenberg K, Geva D, Zuckerman NS, Wax M, Shirazi R, Gozlan Y, Matus
N, Girshengorn S, Marom R, Mendelson E, Mor O, Turner D. Factors Associated with
Virological Failure in First-Line Antiretroviral Therapy in Patients Diagnosed
with HIV-1 between 2010 and 2018 in Israel. Viruses. 2023 Dec 15;15(12):2439.
56: Azuri E, Wax M, Gozlan Y, Wagner T, Mor O. Recent HIV-1 infection in Israel
2017-2021: Evaluation of geenius and HIV-1/2 combo assays for identifying recent
infection detected by Sedia assay and assessment of factors related to recent
infection: Recent HIV-1 infection in Israel. J Clin Virol. 2024 Feb;170:105624.
2017 Abbott Medical- Genotyping of HCV
2020 Gilead-HIV in women
2020 Ministry of Health- serological analysis of SARAS-COV-2
2020 Ministry of Health- establishment of COVID-19 genetic data base via NGS
2021 The Israeli AIDS society- cost analysis of HIV in Israel
2021 Biological Industries Israel Beit Ha’emek Ltd- assessment of buffers for SARS-COV-
2022 Reccanati , Tel Aviv University- Stopping treatment for HBV patients (STOPB)
2017 Selected as best poster at EASL 2017. Shirazi R, Ram D, Rakovsky A, Gozlan Y, Bucris E, Shaked-Mishan P, Picard O, Shemer- Avni Y, Ben-Zvi H, Halutz O, Lurie Y, Safadi R, Ben-Ari Z, Mor ם. Characterization of hepatitis delta infection in Israel: Prevalence and genotypes.
2018 Selected for the prize of best research by the Israeli Association of the Study of the Liver, IsASL, 2018. Shirazi R, Pozzi S, Bassal R, David D, Wax M, Bar-Or I, Asulin E, Lustig Y, Schwartz E, Rawai H, Mendelson E, Ben-Ari Z, Mor O. Circulation of hepatitis E in Israel: high prevalence in pigs, Dromedary camels and in specific human populations.
